The QualityStocks Daily Blog
Covering Micro-Cap and Small-Cap Companies

Our writers and journalists keep investors up to date with the latest news from around the markets. The QualityStocks Blog is another extension of our commitment to help the investment community discover emerging companies that offer excellent growth potential.

WRIT Media Group, Inc. (WRIT) Subsidiary Sees Growth in Entertainment Content in 3D

December 18th, 2014

WRIT Media Group produces films, television programs and entertainment programs for various media formats. In 2011, the company acquired Front Row Networks, Inc. through a capital stock acquisition and completed a senior management restructuring in the summer of last year. WRIT Media, through Front Row, builds shareholder value by leveraging the company’s expertise in the 3D realm within the live concert space to offer a truly differentiated experience at an affordable price.

Front Row Networks (“FRN”) is a content creation company which produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. The company presents live concerts at lower ticket prices to a massive fan base worldwide cost-effectively. Following the concert’s initial run, the distribution rights to the concerts are licensed in both 2D and 3D format. From here, the concert is transferred to DVD and Blu-Ray retailers, Free TV broadcasters, cable and emerging 3D cable channels and mobile streaming providers. Front Row Networks also merchandises customized artist products in movie theaters where the live concert is featured.

Front Row Networks also secures and distributes animated family content, music-related documentaries, and other gaming content that can be distributed via mobile and internet platforms. These offerings align nicely with the company’s strategic goal to acquire a wide range of rights for exclusive programming. The company firmly believes it is well positioned to benefit from the market growth and increased demand for alternative theatrical and mobile content and intends to continue expansion of its exclusive library content going forward.

Incorporated in 2007, WRIT Media Group charts its course as a digital media company with two operating divisions. They are Front Row Networks, a content creation company offering production, distribution, live concert financing, music documentaries, and family programs for theatrical and ancillary distribution; and the “retro” Video Gaming Division, made up of Retro Infinity Inc. and Amiga Games Inc., videogame publishers of classic games for a wide range of smartphone, mobile, and TV set-top devices. The company is headquartered at Beverly Hills, California.

For more information on the company visit

Let us hear your thoughts: WRIT Media Group, Inc. Message Board

Coastal Integrated Services, Inc. (COLV) Engages QualityStocks Investor Relations Services

December 18th, 2014

Coastal Integrated Services announced that it has engaged the investor relations services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with its efforts to broaden influence, attract growth capital and improve shareholder value.

“We are aggressively building a trajectory of success for our award-winning Simply Lids subsidiary,” stated John Newman, president of COLV. “By partnering with QualityStocks we plan to fully utilize social media, blogs and other strategic communication and marketing initiatives that will supplement our business plan and help us engage with existing and potential shareholders.”

QualityStocks will use its network of strategic and influential partners, daily and weekly newsletters, social media channels, blogs and other communication tools to relay COLV’s innovations, news and achievements to shareholders and the broader investment community.

“Our campaigns are built on a strategic blend of social media and communications that are designed to raise brand awareness, build a corporate voice, and better communicate with the investment community,” stated QualityStocks Managing Director Michael McCarthy. “COLV is targeting a multi-billion dollar industry, and we’re honored to help the company build its Simply Lids brand and secure a solid, leading position in the lucrative disposable beverage sector.”

For more information on the company, visit

Let us hear your thoughts: Coastal Integrated Services Inc. Message Board

IFAN Financial Inc. (IFAN) Prepares for Upcoming Technology Availability amid Strong Mobile Consumer Environment

December 17th, 2014

Whether it’s shopping for digital goods, merchandise or a service, 87% of mobile and/or tablet owners buy their goods through their handheld device, according to research firm Nielsen. Inherent to the increasing volume in online transactions via mobile/tablet is the heightened need for security of consumer data. IFAN Financial’s iPIN Technologies subsidiary is emerging as a provider of a secure solution that successfully integrates the functionality of e-commerce and banking with the broader conveniences of the mobile environment.

iPIN Technologies seeks to offer a range of processing services for the evolution of the ecommerce industry, starting with a new method of online selling through debit card payments and processing. The company is currently developing iPIN debit technology in the form of a small device that attaches to any smartphone through the headphone jack. This attachment converts the device into a consumer PIN debit, same-as-cash payment solution and eliminates the need for consumers to share their debit card data with the site on which they’re shopping. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

iPIN Technologies recently announced key milestones in the advancement of its product toward commercialization, which is expected in the first quarter of 2015. These milestones include the development of the user interface, including integration with the Android application package file, as well as the ability to read and transfer data from the iPIN device to the mobile phone application.

The next two milestones under the IFAN/iPIN Technologies license agreement are ongoing and involve posting the status of the transaction to the merchant call back uniform resource locator (URL) and developing the front-end database to enable a merchant processing transaction. Upon final completion, this iPIN Technologies solution will consist of a mobile app, card reader and merchant network that will enable consumers to securely use their smart phone to make purchases.

For more information visit

Let us hear your thoughts: IFAN Financial, Inc. Message Board

One World Holdings, Inc. (OWOO) Subsidiary Featured on Fox’s “The Real”

December 17th, 2014

The One World Doll Project’s creator of the Prettie Girls! Dolls line made a national TV debut on the Fox Television Network talk show, “The Real,” on Tuesday, December 16th. The segment featured One World Dolls co-founder, Stacey McBride-Irby, who surprised the hosts with their very own look-alike dolls.

Before the show aired, McBride-Irby said, “Introducing The Prettie Girls! Dolls to the amazing women of ‘The Real’ and into over one million households across the country is an exciting and proud moment for The One World Doll Project. I look forward to sharing the story of how I came from creating dolls at Mattel to producing The Prettie Girls! doll line that is now being carried by Walmart and Toys R Us.”

Driven by a diverse assembly of outspoken hosts – Tamar Braxton, Loni Love, Adrienne Bailon, Jeannie Mai and Tamera Mowry-Housley, “The Real” strives to reflect home audiences of today. The group is known for saying what women are actually thinking. Their unique perspectives are brought to life through their candid conversations about topics which include their own personal lives to the news of the day to beauty, fashion and relationships. “The Real” is broadcast from Los Angeles, CA.

The Prettie Girls! Dolls have produced an upward trend in media attention since their debut at Toy Fair 2014 and their recent entry into the Toys R Us and Walmart retail channels. Adding to the doll line’s media attention the Prettie Girls! Dolls brand has also been featured in USA Today, JET Magazine, CNN, TVOne, MadameNoire, OK! Weekly and other media outlets.

Corinda Melton, CEO of One World Dolls, noted, “As the Prettie Girls! brand continues to gain visibility and popularity among our target audiences, we expect to have more opportunities like this to showcase our products and tell our story. The mission of this company is to positively impact how young people view and embrace diversity in all aspects of culture, interests, and style, while creating revenue for the Company and value for our shareholders, which we believe we can do simultaneously.”

Established in 2010 by Trent T. Daniel and Stacey McBride-Irby, The One World Doll Project is passionate about changing how retail store shelves represent the doll industry. The Prettie Girls!™ are a collection of fashion play dolls diverse in culture, interests, and style. McBride-Irby, former Mattel® designer most notably known as creator of the So In Style® dolls (the first African-American dolls by Mattel), designed the Prettie Girls! as unique works of art for a growing market yearning for something new to experience.

For more information on the company visit

Let us hear your thoughts: One World Holdings Message Board

Consorteum Holdings, Inc. (CSRH) to Deploy Next-Gen Mobile Engagement Solutions with Public & Private Sector Clients

December 17th, 2014

Consorteum’s wholly owned ThreeFiftyNine Inc. (359) subsidiary aims to work closely with clients to rapidly develop and launch online content using a thin-client server and hybrid mobile application architecture, in conjunction with their proprietary UMI (Universal Mobile Interface), which negates much of the processing load for end-user mobile devices, while also freeing the client of certain development restrictions. A tightly integrated development pipeline between the client and 359 can thus focus on maximum capture of key aspects like characteristics of the target audience itself, goals for the particular brand, and other complex mobile campaign marketing considerations. Considerations like harnessing the big data to drive demographically-focused patron engagement, through features like dynamically scripted conversations and push notifications.

The company’s UMI makes it possible to develop rich, graphically robust content once and then deploy seamlessly everywhere across the mobile space, without having to get bogged down by technical considerations created by the growing diversity of mobile devices out there, or the need to ensure content will be displayed properly on the end-user’s specific device. This amazing ability of the UMI, the result of over five years of engineering and millions of dollars in one-time development costs, to render content in the correct display format irrespective of the end-user’s specific device, shaves massive amounts off the development cycle time generally required to deploy sophisticated content. This ability also frees up much-needed development resources for application to core engagement mechanics, like using the platform’s built in geo-location and geo-fencing technology to conduct geographically-aware initiatives.

All of these technical capabilities combined allow the company’s clients to create highly nuanced marketing campaigns that can target patrons by age, gender or previous responses to other offers, allowing for high return value direct engagement using promotionals like coupons, reward programs, special offers, and interactive sweepstakes. The ability to execute such engagement in a geographically-aware and big data-driven fashion, directly with patrons, using rapidly proliferating mobile devices as the conduit, allows CSRH’s clients to facilitate patron engagement with a level of market granularity that is essentially unprecedented. This kind of end market granularity that can hit the target market at the street level has proven itself to be absolutely key to the success of marketing campaigns and the logistical upside of such solutions isn’t limited to the sphere of commercial deployments either.

The same kinds of solutions that can transform patron engagement in the commercial sphere can also bring tremendous benefits to public sector entities like government agencies. Agencies who really need and can harness the power of big data, as well as geo-location and geo-fencing, to reduce operating expenses and improve the efficacy of a variety of tasks, ranging from personnel and resource management, to the roll out of improved transparency solutions for constituents. For instance, being able to effectively coordinate emergency response in real-time, as well as actively map resources and personnel, is a potential game changer for disaster response or preparedness exercises. Moreover, the robust security capabilities of the company’s thin-client server and hybrid mobile application architecture, empowered by develop once – deploy anywhere delivery, means that the security requirements related to ensuring sensitive/personal citizen information can be handled easily and maintained/updated via the remote server in a consistent manner.

The situational awareness achievable for government agencies when it comes to sprawling personnel and resource networks, through applications developed and deployed using the company’s technology, can save huge sums of taxpayer monies, while alleviating or eliminating daunting backlogs and generally making government more readily accessible. It likely hasn’t even dawned on many government agencies yet just how far they can go with such solutions. Giving users real-time access to the workflow occurring within government offices when it comes to appointments, paperwork, and progress on a given issue, could transform the face of local, state, and federal government itself.

Perhaps more importantly, such solutions allow for unprecedented voter engagement when it comes to developing consensus on a given issue or a piece of legislation. Such solutions could one day also help us transform the nature of how we elect representatives as well, giving us all the tools needed to effect meaningful political change in a geographically-aware and highly granular fashion.

For more information on Consorteum Holdings, visit:

Let us hear your thoughts: Consorteum Holdings, Inc. Message Board

Cleartronic, Inc. (CLRI) Seeking Clear Advantage in BYOD Communication Environments

December 17th, 2014

Cleartronic has been at the forefront of the burgeoning enterprise culture in communications known as BYOD (bring your own device). It has become avant garde for workers to bring their own laptops, tablets and smartphones into the office and to get them all fitted with the necessary software and security so they could all be used on the company’s existing computer network.

But as anyone knows who owns one of these devices and uses it for work purposes, the BYOD philosophy exposes the computer network to disparate or even disconnected operating systems such as Mac, iOS, Android, Chrome, Windows, Windows Phone, Linux and the like.

And with many “mobile” companies, being able to have intercommunication between the corporate office and all the mobile workforce via their mobile devices has been a growing challenge as the BYOD culture has taken hold. Cleartronic has looked to be on the cutting edge of providing the interoperability necessary for disparate mobile devices to all communicate with each other and with the corporate network, and has done so through its VoiceInterop subsidiary.

VoiceInterop, which is wholly owned by Cleartronic, has become a primary choice as a unified communications platform for several U.S. airports, including busy ones like Dulles and Reagan to smaller, more regional hubs like Green Bay and West Palm Beach. And especially during the holiday season, with weather forcing delays, cancellations and re-routing of flights everywhere, having a seamless and unified communication system can be vital to inform all employees of various flight changes, gate changes and travel advisories so airport staff and passengers have the latest information as quickly as possible to reduce or eliminate holiday travel frustrations. And with many BYOD cultures, this means having the ability to send a receive messages over Android devices just as easily and seamlessly as on Windows or iOS devices.

With Cleartronic, Inc., BYOD does not have to mean Bring Your Own Disconnection.

For more information, visit

Let us hear your thoughts: Cleartronic, Inc. Message Board

Ecrypt Technologies, Inc. (ECRY) Building Momentum Off Recent Collaboration

December 17th, 2014

Ecrypt Technologies has been building momentum for its Ecrypt One e-mail security software, and the recent collaboration announcement with Cicada Security Technology sent its stock up to a 52-week high north of 30 cents a share. It has since backed off, but the collaboration with Cicada is still in place and is expected to create a disruption in the cybersecurity space.

While Ecrypt Technologies is moving forward with its e-mail encryption and security software called Ecrypt One, the company recently announced the alliance with Cicada Security Technology to provide an additional vehicle to expand eCrypt’s technology across more channels.

Cicada Security Technology has Cicada II, which not only protects systems logically but also does it physically as well, defending against any tampers or hacks by sending out an alarm in the vicinity of the problem and then shutting down access to all networks and servers until the issue is addressed.

And with Ecrypt Technologies signing on to be a distributor and seller of Cicada products, this can be an opportunity for Ecrypt to use Cicada’s products to forward its Ecrypt One technology as a top secure-email platform for enterprise, government and military communications, and Cicada can rely on Ecrypt’s distribution channels and e-mail encryption software to add yet another level of security to Cicada’s products. This could create a definite win-win opportunity for both companies.

While Ecrypt Technologies stock has come back off its high, there is still an opportunity for growth as the collaboration with Cicada Security Technology starts to take hold in the coming weeks and months. With recent hacking attacks making the news, physical and logical security of computer systems and networks are become more and more important, and Ecrypt and Cicada are working together to stay one step ahead.

For more information, visit

Let us hear your thoughts: Ecrypt Technologies, Inc. Message Boardf

Nhale Inc. (NHLE) Announces $10 Million Financing Commitment

December 17th, 2014

Today after the closing bell, Nhale reported the execution of a term sheet for $10 million in debt financing with Four Twenty Investments, Inc., a Toronto-based private investment group focused on the financing and strategic investments of medical marijuana and similar companies involved in the cannabis industry.

According to the release, Nhale will use this financing to finalize its planned acquisitions of revenue-generating marijuana operations. The company is currently negotiating acquisitions of legal marijuana operations in Washington State, Oregon and Colorado.

“Our relationship with Four Twenty Investments strengthens our position to acquire capable businesses and the brightest talent, and allow Nhale to gain market share within the legal marijuana industry,” stated Lance Williams, President and CEO of Nhale. He added, “This $10 million commitment allows us to deliver on our previously disclosed acquisition strategy beginning in the first quarter of 2015.”

Nhale believes the culmination of the acquisitions currently being negotiated could lead to revenues exceeding $30 million next year. The companies being targeted for acquisition each bring extensive prior experience in the legal cultivation and retailing of medical marijuana, and each as the depth of skills needed to help Nhale become the premier provider of legal cannabis to the marketplace.

For more information, visit

Let us hear your thoughts: Nhale Inc. Message Board

VistaGen Therapeutics, Inc. (VSTA) AV-101 Rivals Ketamine and Other Next-Gen Anti-depressants

December 16th, 2014

On the street ketamine is referred to as “Special K,” a drug popular in the party scene because of its hallucinogenic and other psychotomimetic, or psychosis-like, effects. In the operating room, ketamine has long been used for general anesthesia, and a growing body of research also shows ketamine as highly effective at treating depression, especially in patients who are inadequately treated by currently marketed antidepressants – treatment-resistant patients with Major Depressive Disorder. It’s the dangerous chasm between illicit party drug and FDA-approved general anesthetic that raises concern over using ketamine as an antidepressant. The upside is that the continued focus on depression unveils breakthrough alternative treatments currently in development and a changing paradigm for treating Major Depressive Disorder.

Most currently available antidepressant drugs act on serotonin and related neurotransmitter pathways in the brain and require a long lag in onset of antidepressant effects, usually requiring several weeks of administration before therapeutic benefits are achieved. But about 10 years ago, researchers recognized that ketamine has properties that within a matter of hours help alleviate symptoms of patients with Major Depressive Disorder.

A more rapid-acting antidepressant would have a phenomenal impact on the treatment of depression, and the National Institute of Mental Health (NIMH), part of the National Institute of Health (NIH), is among those researching ketamine’s potential for this indication.

Dr. Carlos Zarate, Chief of Experimental Therapeutics and Pathophysiology at the NIMH, is conducting a Phase 2 clinical trial to examine whether ketamine can cause a rapid-next day antidepressant with longer lasting effects. In a previous study, ketamine produced a rapid antidepressant effect within hours, but the effect lasted less than one week.

As highlighted in an article on NPR, Dr. Zarate’s previous study of 30 depressed patients who were dosed with ketamine did in fact demonstrate changes in brainwave activity that indicated the drug is capable of strengthening connections between neurons in areas of the brain associated with depression.

While these studies and others raise new hope for depression patients, especially for treatment-resistant major depression patients, the primary concerns of using the ketamine for this indication remain.

Among those concerns are the requirement of intravenous (IV) administration in a clinical setting, serious psychiatric effects of the drug, risk of abuse, and the lack of long-term studies. While some clinics provide ketamine that patients can self-administer via IV at home, the practice is a rare departure from the standard practice of monitoring patients when they take the drug.
Pharmaceutical companies hope to dissolve many of these challenges by developing drugs that utilize ketamine’s depression-alleviating properties without the side effects. GLYX-13, made by a company called Naurex, is one such drug.

In the company’s recently reported phase 2b study of GLYX-13, the new data confirmed the efficacy and safety results from an earlier phase 2 study, which documented the drug’s rapid onset of antidepressant activity within two hours and lasting for an average of seven days.

Additionally, GLYX-13 was well-tolerated with no sign of the psychosis-like effects associated with ketamine. This is unarguably of incredible clinical significance when it comes to advances in antidepressants. The catch? GLYX-13 is administered intravenously, which for most patients is an inconvenient if not unrealistic method of administration on a weekly basis.
Medical advances are the results of perpetual fine tunings of initial clinical achievements. On that note, Dr. Zarate at the NIMH also has an eye out for new generation antidepressants such as GLYX-13, Cerecor’s CER-301, and VistaGen’s AV-101.

Dr. Zarate has agreed to be the principal investigator of an expected Phase 2 depression study of VistaGen’s AV-101, a novel drug candidate that that might be more potent than GLYX-13, again with out ketamine-like side effects. Furthermore, AV-101 is administered orally by capsule.

In two randomized, double-blind, placebo-controlled phase I clinical studies, AV-101 was well-tolerated and without signs of sedation, hallucinations or the schizophrenia-like side effects often associated with ketamine and other similar channel blockers.

The phase 1 studies were conducted at the University of California, San Diego, by Dr. Mark Wallace, a colleague of psychiatrist Dr. David Feifel, one of only a few academic psychiatrists to offer ketamine treatment. In a recent New York Times article, Dr. Feifel notes that the biggest challenge of ketamine as an antidepressant is that the effect quickly wears off.
VistaGen’s upcoming phase 2 trial will study AV-101’s ability to improve overall depressive symptoms in adult subjects with Major Depressive Disorder. The trial is expected to start in the first quarter of 2015, be conducted by Dr. Carlos Zarate of the NIMH, and funded by the NIH, which previously awarded VistaGen $8.8 million of grant funding for its preclinical and phase 1 clinical development of AV-101.

VistaGen believes its orally-available AV-101 candidate has the potential to deliver the same therapeutic benefits of ketamine and other NMDA receptor modulators, but without IV administration or side effects. AV-101 is also an FDA fast track designation candidate and demonstrates additional potential in epilepsy, pain and Parkinson’s disease.

Depression is a huge, debilitating and global public health concern. The World Health Organization reports that approximately 350 million people worldwide suffer from depression –according to the NIHM, 7% of that number are U.S. adults. Though the FDA has approved antidepressants for decades, the treatments fail to adequately provide rapid-acting and long lasting benefits in treatment-resistant patients with Major Depressive Disorder. As evidenced by the recent suicide of actor Robin Williams, whose long battle with depression was widely publicized, there is tremendous need for a new generation of safe and fast-acting antidepressants.

The paradigm of depression treatment is shifting away from the use of FDA-approved, long-lag onset drugs toward faster-acting treatments like ketamine. Despite the challenges associated with ketamine, its growing acceptance among the psychiatric community and national media continues to spread. How much more so will the world embrace a new generation of antidepressant candidates, like GLYX-13 and AV-101, that are in sync with this new paradigm but void of the typical challenges?

For more information about AV-101, visit

Let us hear your thoughts: VistaGen Therapeutics, Inc. Message Board

Dominovas Energy Corp. (DNRG) – A Different Type of Alternative Energy Solutions Provider

December 16th, 2014

As energy demands have risen and more and more people have come to recognize climate change’s impact around the world, an increasing number of countries have begun to reassess their energy policies and to pursue non-fossil fuel technology. This global move toward alternative fuel sources has greatly inspired the founders of Dominovas Energy Corp. (OTCQB: DNRG), an energy solutions company.

Nowadays, many countries are primed to invest in projects promoting the research, development and deployment of clean and renewable energy technology that would drastically reduce the reliance on fossil fuels. Alternative energy markets have massive growth potential and, recognizing this, Dominovas Energy is actively moving to allocate financial and intellectual capital to address the need for energy solutions that produce continuous, dependable and efficient “green” power.

Dominovas Energy is especially focused on developing utility-sized fuel cell systems that generate electricity using alternative fuels. By concentrating on bringing this leading-edge technology to many markets, the company hopes to accelerate the transition to a fuel cell economy.

At the heart of the company’s fuel cell division is the proprietary RUBICON Solid Oxide Fuel Cell technology. The fuel cell is designed to lessen current air pollution and foreign oil import dependency levels. It can turn multiple fuel stocks, including diesel, methanol, bio-diesel and hydrogen, into various customizable power output channels. It can also achieve more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100KW to multi-megawatt power arrays.

In addition to being quiet, compact, flexible, highly efficient, and exceptionally clean, the RUBICON fuel cell curbs emissions of the greenhouse gas carbon dioxide. The fuel cell is more efficient than conventional energy processes because it converts the chemical energy of the fuel directly into electricity without going through a transitional combustion step. The fuel cell is also cleaner than any carbon-fueled combustion process, even when using carbon fuel as its hydrogen source. Plus, the heat and water produced in the conversion process can be used for water and space heating.

The positive, large-scale impact of fuel cell technology is clear, and Dominovas Energy is on a mission to deploy and implement its RUBICON technology internationally. The company firmly believes in the impact its advanced technology can make on the world and has set upon a mission to fill this need where economically viable.

For more information, visit

Let us hear your thoughts: Dominovas Energy Corp. Message Boards Features Sibling Group Holdings, Inc. (SIBE) in Exclusive Interview

December 16th, 2014


Sibling Group Holdings, an educational technology holding company, today announces its recent interview with, Inc. is now available at Investors can listen to the whole interview at

David Saba, President of Sibling Group, discussed the company’s mission, unique product and service line and business model, as well as its growth strategy and plans for 2015.

“The worldwide education industry is a $4.3 trillion market. Sibling Group Holdings is looking at each one of the different segments within that market and acquiring companies that have the ability to rapidly expand either through providing a very unique set of content that drives improved learning or a very unique set of technologies that leverage that content into a much greater market share. The first two companies that we’ve looked at are Blended Schools Network, which serves the K-12 market, and Urban Planet Mobile, which serves the international market for English language with acquisition completion scheduled for December. Blended Schools Network was acquired in May and we’re expecting to close the Urban Planet Mobile acquisition before the end of this year,” Mr. Saba said.

He added, “In just nine months we’ve really started to accelerate the growth of Sibling as we’ve been able to realize two of the key elements of our strategy — finding new sales outlets for our existing products and meeting demand for those products in the international market. The next phase of the strategy is to go up and down the education delivery spectrum so we can find potential opportunities to work into the post-secondary market, which includes colleges and universities as well as into the pre-K market. We feel both of those are ripe for disruption.”

For more information on Sibling Group Holdings, visit

Let us hear your thoughts: Sibling Group Message Board

The Core of Technology Applications International Corp.’s (NUUU) Diverse Business Model

December 16th, 2014

Technology Applications International operates through two drastically separate subsidiaries to maintain a core portfolio trekking toward success. The company’s first subsidiary, Rejuvel Int’l, Inc., produces and sells a line of anti-aging skincare products. NueEarth, Inc. engages in the environmental management and water purification industries.

Rejuvel Int’l has developed its skincare line of products using exclusively licensed technology from the National Aeronautics and Space Administration (NASA) and Administrators of the Tulane Educational Fund (U.S. Patent No. 6,730,498). Rejuvel’s flagship anti-aging facial product works by stimulating human fibroblast skin cells that rebuild skin for a firm, healthy and youthful appearance. The company has been awarded a “seal of approval” from the Space Certification program.

In October, Rejuvel Int’l completed a clinical study in which doctors, nurses, clinical study, recruitment professionals, quality assurance and trained evaluators and a large network of consulting physicians at the at Essex Testing Clinic in Verona, New Jersey, tested the skin-care product’s efficacy. Scientific Measurements results after six weeks of use by 32 subjects are as follows:

• 78% of subjects: fine lines/ wrinkles were significantly reduced
• 88% of subjects: under eye discoloration significantly improved
• 78% of subjects: firmness/ elasticity significantly improved
• 97% of subjects: skin moisture significantly improved

Next, NUUU will voluntarily submit these testing claims to the U.S. Food and Drug Administration.

On the other side of NUU’s business model is NueEarth, which strives to address global water pollution by utilizing e-beam technology to degrade or remove trace quantities of antibiotics and endocrine disrupting chemicals left behind in the conventional drinking water treatment processes. The application of this technology also eliminates the need for treating water with chlorine and chlorination by-products that may be carcinogenic (cancer-causing) or have other toxicological effects with consumption.

E-beam accelerators are one of the most promising alternative technologies for the purification water through advanced oxidation/reduction process induced by high-energy electrons that are blasted into biologically or chemically polluted water. This process enables the ultimate destruction of the buffet of dangerous chemicals in treated water whereas filter-based technologies retain the unwanted contaminants.

While using e-beam accelerators for chemical purification of drinking water, municipal and industrial wastewaters is still considered an “emerging technology,” multiple pilot plants and a few full-scale treatment facilities have already been established around the world. NueEarth’s plan is to develop various applications that will take advantage of the e-beam particle accelerator technology to remove the aforementioned toxicity and pollutants from wastewater, drinking water, municipal sludge and even water contaminated by the fracking process.

NUUU management team is working to establish brand recognition in the marketplace via advancements in its two subsidiaries along with well-respected associations and strategic marketing initiatives that ultimately contribute to corporate growth.

For more information on NUUU visit or

Let us hear your thoughts: Technology Applications International, Inc. Message Board

Intercept Energy Services Inc. (IESCF) Stakes Its Energy Claim in North America

December 16th, 2014

Intercept Energy Services, an oilfield services company that specializes in water-heating for various fracking operations, has made it pretty clear of late that it will stake its growth claim in North America, which has quickly become the largest oil producer in the world thanks to huge fracking efforts on private lands in Texas and especially in the northern plains of the Dakotas.

Intercept Energy, which recently completed a $50,000 private placement of stock to fund some expanding operations in the Bakken oil field in North Dakota, is coming off an encouraging quarterly earnings report in which revenue for the quarter was up more than 120 percent to $800,000 year-over-year, while the 2014 overall revenue number was up nearly 90 percent from 2013 to $2.6 million.

Intercept Energy Services recently indicated strong interest and existing plans to expand operations throughout North America, but is taking a current keen interest in the Bakken shale fields. The company increased its investment from three patented heating units to five.

The units, known as HE Heaters, are gaining momentum with fracking operations because they heat water and do not give off radiant heat, which has shown to be more environmentally safe, and safer for workers as well since the heaters have no open flame with which to contend. The heat that is given off is put back into the heating of the water.

With the boom of shale fracking in the Bakken fields continuing with little downturn expected in the long term, there is an opportunity for Intercept Energy Services to provide its HE Heaters as a prominent tool on several plays across North Dakota, which may mean an opportunity for growth that could match the growth of the Dakotas and U.S. oil production in general.

For more information, visit

Let us hear your thoughts: Intercept Energy Services, Inc. Message Board

Miraculins, Inc. (MOM.V) (MCUIF) Revolutionary Scout DS® System Provides Highly Accurate, Non-Invasive Diabetes Screening Methodology

December 16th, 2014

Diabetes is the fastest growing disease in history with some 387M or more cases globally estimated this year by the International Diabetes Federation (IDF), a figure that is set to rise roughly 53% over the next two decades. The most disturbing statistic is the 175M or more of those cases that go undiagnosed. The IDF data paints an alarmingly clear picture, diabetes is on the rise in every country on earth; in fact, one out of every 12 humans has diabetes and one out of every two people with diabetes doesn’t even know they have it. The IDF estimates that as many as 628M people globally are pre-diabetic or have Type 2 diabetes (adult-onset or non–insulin-dependent diabetes), with projections through 2030 indicating a 45% jump to around 912M.

Here in the U.S. we are spending more on healthcare to combat diabetes than anywhere else on the planet, with $612B (or 11% of all healthcare spending on adults) spent in 2014 alone, and the American Diabetes Association’s (ADA) data indicates that not only is diabetes the number seven killer in the country, it was also a leading underreported cause of death. Some 40% of people who died of diabetes did not have it listed anywhere on the death certificate according to ADA’s research, and the Centers for Disease Control and Prevention (CDC) estimates that if this trend continues as many as one out of every three Americans will have diabetes by 2050. Troubling statistics indeed when one considers the nearly 5M fatalities this year in the U.S. from diabetes, or one death every seven seconds.

Last year, over 79k children developed Type 1 diabetes (roughly 10% of all cases, formerly known as juvenile-onset or insulin-dependent diabetes) and over 21M births were affected by diabetes during pregnancy as well. Moreover, despite the incident rate being highest among persons aged 40 to 59 years, some 208k Americans under the age of 20 are estimated to have been diagnosed this year according to the ADA. This clearly documents that Type 2 diabetes, once virtually unheard of in people under 30, is now rapidly on the rise, with childhood obesity playing a major role.

Type 1 diabetes can be averted if caught early and diabetics can even turn the disease around completely with proper diet and exercise, but the high number of undiagnosed cases is a serious red flag here, pointing directly to the costs, complexities and invasiveness of testing. Early detection and intervention is absolutely key to preventing Type 1 diabetes, and with average medical expenditures as much as 2.3 times higher for diabetics than those without it, public health organizations and governments are now starting to get serious about creating initiatives designed to tackle the problem.

Many people go untested due to the invasiveness or daunting logistics of existing testing methods, involving blood draws, fasting, trips to the doctor and/or lab, and waiting for test results to come back. The common A1C test for instance (sometimes also called the HbA1c test), which measures an individual’s average blood sugar level over the past few months, requires a sizeable blood sample and is the most common route for testing. The FPG test (fasting plasma glucose) or the OGTT test (oral glucose tolerance, commonly done to check for diabetes that occurs with pregnancy, or gestational diabetes), while less expensive and generally very easy to do compared to the A1C, are similarly problematic, given that patients must fast for 8 to 14 hours prior to taking the test and must still give a blood sample(s).

People’s reluctance to get tested and the subsequent healthcare costs associated with increased morbidity, may have finally met their match though in the form of the novel, non-invasive Scout DS® system from Miraculins, Inc. (TSX-V: MOM) (OTCM: MCUIF). This first-of-its-kind device is a sleek looking, small form factor tabletop system, featuring an LCD display and an arm rest that the patient places their forearm onto for the test. After only about 80 seconds the device painlessly produces a highly accurate score on a scale from 0 to 100 using a series of LED lights and sensors. The device uses a well-established testing methodology called skin fluorescence spectroscopy (SFS) to measure advanced glycation end products (AGEs), which have been vetted through numerous studies over the past 25 years as a highly sensitive metric for gauging the cumulative impact of abnormally high blood sugar and oxidative stress on the body.

Until recently, AGE measurement required a punch biopsy of the skin big enough to require a stitch and a costly/complex assay for which only a handful of academic laboratories had the capability, making this approach to screening for diabetes essentially non-commercially viable. The Scout DS however uses quantitative SFS (multivariate spectroscopy using a unique algorithm) to measure collagen cross-links and other fluorescent AGEs, via a set of unique UV/Blue LEDs to stimulate fluorescence, as well as some White LEDs to compensate for skin tone variations. With more than 3k subjects to date tested in prospective clinical trials, the accuracy and efficacy of the Scout DS for doing rapid, non-invasive screening of pre-diabetes and Type 2 diabetes, by measuring diabetes related biomarkers in the skin, now looks to be firmly established.

The efficacy of this rapid testing technology was even recently demonstrated in a peer-reviewed study (ENGINE) of the Scout DS published in the Journal of Clinical and Translational Endocrinology. The study showed the device’s ability to detect abnormal glucose tolerance just as well as (if not better than) FPG or A1C testing, all without fasting or blood draws, adding further credence to the commercial viability of the Scout DS as a rapid non-invasive screening system for diabetes, as well as the accuracy and robustness of the innovative SFS/AGE testing methodology which lies at the heart of the device’s design. The Scout DS is 61% more sensitive than A1C and 100% more sensitive than FPG (ENGINE study), with a 93% detection rate for Type 2 diabetes (TCOYD1 study), and is 1.4 times better than RCG with an equivalent false-positive rate (random capillary glucose, Greece study), yet the device easily works on people with dark skin (LSS study versus OGTT).

In China, which has overtaken India as the world leader in diabetes cases, with upwards of 92M diabetics (again, nearly half of whom are undiagnosed), there is a massive target market for such a device as the Scout DS. Miraculins hasn’t wasted any time acquiring inroads to this target-rich environment and executed a definitive agreement in August to sell and distribute up to $90M worth of Scout DS devices via Hong Kong-based Catalyn Medical Technologies, Ltd., with Cachet Pharmaceutical Co., Ltd. already tapped as exclusive distributor for mainland China.

Also in August, Miraculins detailed their fast-track strategy for obtaining de novo FDA classification (intended for “novel” devices with a low risk profile) on the Scout DS, with a pre-submission designed to follow up on last year’s filing for feedback from the FDA regarding a clinical/regulatory roadmap for marketing clearance, in light of the reasonable assurance of safety and effectiveness of the device, as well as the absence of any existing or comparable device on the market. Obtaining de novo status from the FDA would put the Scout DS on the road to a Class I or Class II medical device classification (cheaper and easier than a Class III designation) and confidence is high at Miraculins that the FDA will be cooperative, especially when the planned data to be gathered and submitted is supplied.

For more information, visit

Nhale Inc. (NHLE) Revenues Set to Eclipse $30M in 2015 Pending Current Deal Closures

December 16th, 2014

Nhale has announced that its revenue projections are expected to exceed $30 million in 2015 in large part due to deals currently under consideration in states where recreational marijuana is legal. Nhale is currently pursuing transactions in Washington State, Colorado and Oregon for grow operations with this combined deal flow if all of them come to fruition.

Lance Williams, President and CEO of Nhale, commented, “Nhale’s entry into the legal marijuana cultivation market could not come at a better time. Incredible demand is creating big opportunity and driving new solutions.” He also said, “Nhale is positioning itself as an effective, long-term strategic partner, with dedicated focus and the leadership capability to develop and carry out plans.”

Legal marijuana growers account for $14 billion a year in sales in California alone. According to TIME, this sales figure makes it the state’s most valuable cash crop. As reported in a study by researcher Jon Gettmen, PH.D, in Oregon, marijuana is the state’s second-largest cash crop behind apples.

“We are encouraged to have these significant growth opportunities and believe they are a tribute to the professional advantages we bring to the table. We look forward to working with these companies and growing along with the industry as marijuana transforms into a legal commodity throughout the U.S.”

Nhale™ is a U.S. company actively pursuing acquisition opportunities in the rapidly expanding marijuana industry. NHLE is focused on acquiring companies with proven business models positioned to make a significant impact within the medical and recreational cannabis market. The company brings operating talent, tools and leadership to emerging companies in the space, promoting industry awareness and developing economically sustainable partnerships while increasing shareholder value.

For more information on the company visit

Let us hear your thoughts: Nhale Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) – Developing Novel Therapies to Answer Medical Needs

December 15th, 2014

When used for medicinal purposes, cannabis can have a number of beneficial effects from appetite stimulation to pain relief. Cannabinoids, which can serve as pain relievers, could therefore be used as (or in) medicine for cancer patients. Millions of patients could benefit from the therapeutic effects of these compounds, especially those seeking safe, regulated, easy to administer cannabis-based therapies.

Cannabics Pharmaceuticals is committed to meeting unmet medical needs and designing leading-edge technologies in the field of cannabinoid-based therapies. The company’s research and development efforts are presently focused on the:

• development of administration routes of active cannabinoids

• identification of the interactive, beneficial therapeutic effects of assorted cannabis-based compounds in varied indications

• development of personalized cannabinoid therapies for cancer patients

Through research, Cannabics has collected precious knowledge about the effectiveness of cannabis strains as therapies for specific symptoms. The company continues to develop its genetic and phenotipic database in order to provide better treatments for incapacitating and incurable ailments.

Cannabics’ stated objective is to be one of the first (and few) companies in the world to commercialize cannabis-based medical products that are indication-specific and have been clinically tested. To reach this goal, Cannabics is currently preparing for the launch of a series of rigorously controlled clinical studies in leading medical centers in Israel, where the company’s research and development division is based.

Cannabics Pharmaceuticals is an emerging drug development company that is employing novel technologies in order to develop innovative cannabinoid-based therapies for a range of debilitating ailments. The company is focused on developing and marketing advanced drugs, therapies, food supplements and administration routes based on active ingredients found in strains of the cannabis plant. Cannabics’ flagship product is Cannabics SR, a slow-release medical cannabis capsule designed as a pain-relieving therapy for cancer patients.

For more information, visit the company’s website at

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

The One World Doll Project (OWOO) Featured Alongside Industry Behemoths in USA Today Article

December 15th, 2014

A recent article in USA Today chronicles the toy industry’s inclusion of diversity in the doll segment, along with how doll designers are meeting consumer demand for more multicultural representation.

Read the full article here

Minorities are expected to become the majority in the United States by 2040, at which time Geoscape estimates that non-white spending will surpass white spending. The shift ushers in new waves of consumer demand for diversity in just about every corner of the market. For the toy industry in particular, changing U.S. demographics strengthen consumer demand for multicultural diversity, something that progressive toy companies are finding has incredible selling power.

Among its deeper look into the toy industry, the USA Today article also features heavy-hitting industry players like American Girl and Mattel (NASDAQ: MAT) along with a lesser known, but equally as innovative company rapidly making its mark with its multicultural doll line.

Barbie designer Stacy McBride-Irby is a well-recognized figure in the doll making business. McBride has long been an advocate for more diversity and accurate representations of race in the doll industry. In 2009 she created for Mattel the “So In Style” line of African-American dolls. Straying from the typical white Barbie mold, the dolls were designed with fuller lips, wider noses and varying skin colors.

The following year, McBride-Irby left Mattel and started the One World Doll Project, subsidiary of One World Holdings (OTC: OWOO), to make a significant positive cultural impact through the doll category and create positive self-image in young women and girl around the world.

“I do it because I am an African-American woman,” Mcbride-Irby told USA Today. “I wanted to focus on dolls that are not represented on the doll shelves.”

The One World Doll Project in 2013 released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations to connect with a diverse demographic of girls and encourage them to reach for their potential.

One World Holdings has distribution deals with Toys “R” Us, HEB,, Tuckers Toy Shop,, and recently expanded its international retail presence with the People’s Pharmacy store chain in Belize. In November, One World Holdings received its first order from Walmart, just time to establish a presence for the holiday season.

On par with consumer demand, The One World Doll Project is earning considerable recognition in the media as well as the toy industry. In addition to its mention in the recent USA Today article, The Prettie Girls! dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine,,, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and

The media coverage reflects the company’s solid commitment to its cause and its growing presence in the competitive and culturally diverse toy market.

For more information visit

Let us hear your thoughts: One World Holdings Message Board

Receive a Daily List of the Best Investment Newsletter Recommendations

December 15th, 2014

QualityStocks provides online tools and resources to connect subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer many tools to execute this mission, but one of the most liked is our daily Top 3 List.

The Top 3 List allows investors subscribed to The QualityStocks Daily to quickly see which newsletters picked the best performing stocks of the day, saving you time and potentially money you’re missing out on.

To sign up now, visit

With The QualityStocks Daily, you don’t have to wade through the countless investment newsletters to find the day’s top stock picks. We filter out the newsletters making the right call and deliver them right to your inbox.

And as always, subscribers also have access to The QualityStocks Daily Chart, a collation of each day’s picks from the more than 850 investment newsletters we’re tracking every day.

Let us hear your thoughts below:

WordLogic Corp. (WLGC) Inks Deal to Monetize Intellectual Property for General Electric (GE)

December 15th, 2014

WordLogic today announced that it has entered into an agreement involving exclusive rights to monetize specific patented intellectual property in General Electric’s portfolio. WordLogic, a predictive intelligence technology company that creates patented solutions for mobiles, tablets and desktops was approached by GE due to its leadership position in predictive technologies and foundational patent portfolio.

Frank Evanshen, Chief Executive Officer of WordLogic commented, “We are extremely pleased to start a relationship with such an impressive company that is using the best technologies to provide solutions in energy, health and home, transportation and finance.”

The news can only be referred to as a huge win for Wordlogic. General Electric (NYSE: GE) is a diversified company with products and services that range from aircraft engines, power generation, oil & gas production equipment, and household appliances to medical imaging, business & consumer financing and industrial products. The company’s global pervasiveness involves 307,000 employees and has a cumulative market cap that approaches $250 billion dollars.

WordLogic (OTCQB: WLGC) develops, markets, licenses and sells advanced predictive platform software designed to accelerate information discovery and text input. The company’s innovations can operate on a wide variety of devices including smartphones, PCs, cell phones, Smart TV, media players, automotive navigational systems, infotainment and game consoles. WLGC’s intellectual property portfolio includes U.S. and European patents and numerous pending patents.

For more information about on the company, visit

Let us hear your thoughts: WordLogic Corp. Message Board

Coastal Integrated Services Inc. (COLV) is “One to Watch”

December 12th, 2014

Coastal Integrated Services Inc. is targeting the multi-billion dollar disposable beverage sector with the application of the unique technology and innovation developed by its wholly owned subsidiary Simply Lids, Inc. The company’s specialty is disposable beverage lids in the food services industry.

Simply Lids’ patented technologies provide a safer, more enjoyable drinking experience, without splashing or spills. The company’s product designs also enable the added benefit of unique marketing opportunities that have never been realized in this industry sector.

The current standards for beverages are either a flimsy lid that requires the user to tear a pie-shaped mouth hole, or a tiny hole that you have to suck the liquid out like a child’s slippy cup. Frustrating and unsafe. The refreshingly improved design and customization options offered by Simply Lids allows users to enjoy their beverages like there is no lid at all while keeping liquid from splashing out.

The lids are aimed at a $20 billion dollar opportunity in the food services industry where there is astonishing no competition. The use of a new more environmentally friendly plastic with a lower carbon footprint also ensures that Simply Lids / COLV is working towards a more sustainable product for future generations. To date, Simply Lids has won the innovative new product award at the Seattle Coffee Fest Show, received designation as 10 out of 10 by Trend Hunter which indicates placement in the top 20 trends for 2014, and nomination for the prestigious Edison Award.

For more information on the company, visit

Let us hear your thoughts: Coastal Integrated Services Inc. Message Board

Pan Global Corp. (PGLO) Views India’s Power Needs as Pivotal to Revenue and Growth Opportunities

December 12th, 2014

Power or electricity is an integral spoke in the wheel of infrastructure. It directly affects economic growth and a nation’s ability to survive overall. The existence and development of adequate power infrastructure is particularly essential for sustained growth for the Indian economy. With a production of 1,006 terawatt hours (TWh), India is the fifth largest producer and consumer of electricity in the world after US, China, Japan and Russia.

The Indian power sector is without question one of the most diversified in the world. Sources for power generation range from commercial sources such as natural gas, coal, lignite, hydro, oil and nuclear power to other viable non-conventional sources such as wind, solar, and agriculture and domestic waste. The demand for electricity in the country is growing rapidly and is expected to grow further in the years to come. In order to meet the increasing requirement of electricity, massive addition to the installed generating capacity in the country is required.

Pan Global views India’s power challenges as a pivotal opportunity within its mission to deliver shareholder value today and into the future. The company directs its intellectual capital, time and resources toward investing in green energy technology and infrastructure around the world. PGLO fuels its investments in renewable energy and energy efficiency technology and “green” projects that make up solutions for basic infrastructure.

There are currently a number of amateur hydroponic greenhouse operators in India. Pan Global is interested in becoming the first commercial operation that supplies the market of large food chain retail stores and high-end hotels. Under hydroponic greenhouse growing conditions the company believes it can produce high quality, organic produce for consumers there. Overall, Pan Global is focused on developing a series of environmentally sustainable projects that show promise for robust financial return. Some of the project opportunities in India include development of small hydro power generation, agriculture under controlled growing conditions, solar PV projects and geo-thermal power and green buildings.

For more information on the company, visit

Let us hear your thoughts below: Pan Global Corp. Message Board

Boreal Water Collection Inc. (BRWC) Catches Powerful Customized Bottled Water Wave

December 12th, 2014

In a day and age where marketers are frazzled more than ever about how to reach small, individual groups with their messages, it was just a matter of time before an innovative company emerges with the expertise to take water, the ultimate commodity, and transform it into a powerful, thirst-quenching, customized marketing tool.

Boreal Water Collection Inc. (OTC: BRWC) is a personalized bottled water corporation that specializes in providing premium custom bottled water for companies and their customers. Leveraged for publicity, promotion, marketing, internal use or a specific event, Boreal Water offers fully integrated turnkey service, with prize-winning Boreal Water private label water, made-to-order labeling, and distinctive water containers. Beneficiary of the ultimate market differentiator, Boreal Water has exclusive access to two untouched and abundant springs, one an award-winning source deep in the wilds Saint-Élie-de-Caxton in Québec and the other in the prestigious Catskill Mountains in New York. With exclusive unlimited exploitation rights, Boreal Water has a confirmed volume in excess of thousands of millions of gallons.

Commenting on the company’s Q3 performance in 2014, Ms. Francine Lavoie, CEO of Boreal Water Collection Inc. commented, “We strengthened the core of our product line, expanded our client list globally, and managed to drive growth with disciplined decisions, bold innovation, and focused execution.” Commenting further, Ms. Lavoie noted, “I am very pleased that we were able to increase our revenues during the third quarter of this year, and we are projecting to exponentially increase those revenues in the coming year ahead. Our solid execution and expense discipline will allow us to rapidly grow production and deliver a strong finish to the fiscal year along while increasing our long-term shareholder value.”

BRWC’s all-inclusive customer roster is enviable by any measure. Partnering with the likes of Infiniti, Guess, LaCosta, Porsche, Ritz Carlton, Tommy Hilfiger, Saks Fifth Ave, Re/Max, BMW Balance Water, Wa-taah Water, Fred Water, Dean & DeLuca, the Quin Hotel, WestHouse New York, the Surrey New York City, Bouchon Bakery, Princeton University and 3M, BRWC’s credibility in the customized bottle water space is undeniable.

For more information on the company, visit

Let us hear your thoughts: Boreal Water Collection, Inc. Message Board

VistaGen Therapeutics, Inc. (VSTA) Embarking on Key Stage 2 Clinical Trial of Potential Breakthrough Major Depression Therapy

December 12th, 2014

With the very public suicide of actor/comedian Robin Williams recently, the battle with major depressive disorder, or MDD, has moved even more into the public light. VistaGen Therapeutics, Inc. (OTCQB: VSTA) has become one of a small group of companies developing a new generation of antidepressant drugs to combat depression where current antidepressants and other therapies have come up short.

VistaGen is slated early in the New Year to begin a Phase 2 clinical trial of its AV-101 with the National Institute for Mental Health (NIMH), the mental health arm of the National Institutes of Health (NIH), builing on encouraging signs of safety and the drug’s potential to better combat major depression without the lag in onset of therapeutic benefits and some of the serious side effects often associated with currently-available anti-depression therapies and treatments.

With nearly $9 million of prior support from the NIH, VistaGen has been working diligently to develop AV-101 for various diseases and conditions of the central nervous system (CNS), including depression, chronic pain and other CNS disorders, and AV-101 is reportedly showing the notable potential for success in combating one of the most prominent disorders in the world – one which is estimated to affect about 1 in 20 people globally and indirectly impacts families and friends of those sufferers. That potential has now caught the attention of the NIMH, which is expected to collaborate with the company and sponsor its upcoming Phase 2 clinical study of AV0-101 in major depression.

In its NIH-funded Phase 1 clinical trials in healthy volunteers, AV-101 was safe, with no adverse side effects. In those studies, multiple subjects on AV-101 (none on placebo) expressed positive feelings of well-being similar to ketamine’s rapid-onset antidepressant effects, without any of ketamine’s serious side effects. There were no reports of hallucinations, sedation or any schizophrenia-like effects which have been reported with drugs such as ketamine and similar treatments that have produced what are called rapid-onset antidepressant results.

This Phase 2 trial is due to be both started and completed in 2015, offering hope for a potential safe and effective breakthrough treatment for major depression, something that has eluded patients and healthcare professionals for decades.

For more information, visit

Let us hear your thoughts: VistaGen Therapeutics, Inc. Message Board

Falcon Crest Energy (FCEN) Focused on Proven Petroleum Reserves in North American

December 12th, 2014

It has been commonly said that there is no energy without resources and the task to discover and develop such resources is a daunting yet vital task for the world’s economy. Fortunately there are companies who thrive in the space – deploying high levels of expertise and technical know-how that in turn are responsible for delivering the quality of life so many of us enjoy.

Falcon Crest Energy is one such company working to make these notable and necessary contributions within the oil and gas industry. With its efforts centered within the oil and gas exploration and production arena, FCEN currently is focused on developing properties and opportunities in North America.

The company is not shy about being laser focused on the effectiveness and efficiencies of its operations. The company is executing a strategy to maximize its production capacity by focusing on acquisitions and joint ventures. These plans subsequently maximize its profits through the strategic acquisition and liquidation of select oil and gas properties. As a result, Falcon Crest looks to increase production levels and thereby create shareholder value by leveraging the latest improvements in oil and gas production technologies. Falcon Crest works to reduce the inherent risk that comes with all oil and gas exploration activity by developing proven petroleum reserves.

Formed in 2006 by Panther Energy, the company’s name transitioned to Falcon Crest Energy in the summer of 2014. The company now has a number of notable partners—C. K. Adams, L & J Operating and Pacer Energy—consulting for the business.

C. K. Adams is a professional engineer. Since the mid 1970’s Adams has specialized in petroleum engineering from Casper, Wyoming and adds experience and expertise to Falcon Crest Energy. Pacer Energy has made its name as a prominent lease acquisition and title opinion company in Gillette, Wyoming.

For more information, visit

Let us hear your thoughts: Falcon Crest Energy Message Board

VistaGen Therapeutics Inc. (VSTA) AV-101 Poised to Emerge as a Leading Candidate in Multibillion Dollar Global Antidepressant Market

December 12th, 2014

Depression affects nearly 7% of all adults in the U.S. and over 350M people worldwide according to the World Health Organization, and it is a major contributor to overall disease statistics. GBI Research forecasts the global antidepressant market as growing to around $13.4B by 2018 with a CAGR of approximately 1.8%, even though the primary market component, serotonin re-uptake inhibitors (SSRIs), has continued to produce red flags like ill-served patients and a variety of dangerous side effects.

The FDA-approved anaesthetic ketamine is currently used for starting and maintaining anesthesia, with the chief applications being to induce sedation during intensive care or as a serious pain killer. However, ketamine has also more recently been shown to have significant effect as a fast-acting antidepressant in depression patients that don’t respond well to the typical depression medicine available on the market today, such as Prozac, which mostly target monoamine neurotransmitters. Pharmacologically classified as an NMDA (N-methyl-D-aspartate) receptor antagonist, ketamine induces a trance-like state and, in addition to pain relief and sedation, causes memory loss. Ketamine is classified as a dissociative agent alongside other drugs in its class, like PCP (phencyclidine), with side psychotomimetic effects like confusion, seeing flashing lights and bright color, things that make it popular as a club drug of abuse. The clinical and therapeutic emergence of ketamine in major depressive disorder (MDD) has naturally been significantly slowed down, despite its efficacy in placebo-controlled studies at the NIH, due to these acute psychosis-like side effects (and the potential for abuse, despite having to be administered intravenously), opening up a massive opportunity for a new generation of safe and effective, fast-acting drugs giving the benefits of ketamine while minimizing or eliminating these psychotomimetic side effects.

The rush is now officially on to bring such fast-acting antidepressant agents to market, but to gain widespread approval and clinical acceptance, such agents would ideally need to have comparably robust efficacy and rapidity of onset to intravenously (IV) administered ketamine, according to the Global Therapeutic Head of Neuroscience at Johnson & Johnson (NYSE:JNJ), Husseini K. Manji, MD, FRCPC. Dr. Manji has also noted that to truly gain widespread acceptance, such agents really need vital characteristics that further distinguish them from ketamine, like oral availability and a toxicology profile that would make the agent viable for daily or even chronic use.

One such promising new generation agent, GLYX-13, is an IV-administered partial NMDA receptor agonist being developed by a private company, Naurex, Inc. which raised $18M during its launch of Phase 2 efficacy testing for GLYX-13 back in 2011, and that was without any prior clinical efficacy data. To date, based mostly on the potential of GLYX-13, which is currently Phase 3-ready, Naurex has raised over $160M from a broad array of sector heavy-hitters, including Baxter Ventures, the venture capital arm of Baxter International (NYSE:BAX). Naurex’s latest raise brought in $80M this December 3, largely due to positive Phase 2 data showing robust and sustained antidepressant effect in major depressive disorder patients, again with giants like Baxter and Genesys (NSE:GENESYS) on board.

Another promising new generation antidepressant agent, currently entering Phase 2 development, the same pipeline stage as GLYX-13 was in when Naurex raised that first $18M chunk of their development war chest, is AV-101 from VistaGen Therapeutics (OTCQB: VSTA). VistaGen’s share price is highly accessible to investors and the company is currently poised to launch an important Phase 2 clinical efficacy study of AV-101 in early 2015. The company is planning to collaborate with the National Institute of Mental Health (NIMH) under a Cooperative Research and Development Agreement (CRADA) expected to provide NIH sponsorship of the study.

AV-101, a prodrug which is rapidly and enzymatically converted into the established and highly potent NMDAR antagonist, 7-chlorokynurenic acid (7-Cl-KYNA), after crossing the blood-brain barrier, is novel, orally available (in a capsule), non-sedating, and non-hallucinogenic, with no signs of the schizophrenia-like side effects associated with other NMDA channel blockers, such as ketamine. VistaGen’s focus on the glycine binding site (GlyB) within the NMDAR could prove to be one of the best approaches in the new generation antidepressant space to date, potentially offering compelling advantages over competitors like oral-availability and a highly selective method of action.

VistaGen also has an ace up their sleeve, a highly-respected NIH physician with considerable clinical experience using ketamine in major depression, Dr. Carlos Zarate, Chief of the Experimental Therapeutics & Pathophysiology Branch (ETPB) and Section on the Neurobiology and Treatment of Mood Disorders at the NIMH. Dr. Zarate will be conducting the NIH-sponsored Phase 2 efficacy study of AV-101 for major depression early next year. They should have the CRADA hammered out sometime early next month. Savvy investors will want to keep an ear to the ground for developments on AV-101, as this candidate could emerge as one of the leading new generation antidepressants, with therapeutic potential in a variety of central nervous system (CNS) disorders as well, including chronic neuropathic pain, epilepsy and even neurodegenerative diseases like Parkinson’s disease and Huntington’s disease.

For more information on VistaGen Therapeutics, visit:

Let us hear your thoughts: VistaGen Therapeutics, Inc. Message Board